Analysts: Alexion Offers a Buying Opportunity and 4 New Opinions Investors Must Read

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): The company’s price target has been increased by Deutsche Bank after the firm met with management. The firm believes the Juxtapid U.S. launch is already ahead of expectations, and it keeps its Buy rating on the stock.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

AEGR

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business